Abstract
Osteoarthritis (OA) is a chronic disease that requires a multimodal therapeutic approach. The aim of this study was to evaluate the effects of undenatured type II collagen (UC-II) as compared to robenacoxib in dogs affected by OA. Our hypothesis was that the two compounds would be similar (non-inferiority) in improving mobility. To test this hypothesis, a complete orthopedic examination, x-ray and the Liverpool Osteoarthritis in Dogs (LOAD) survey were performed in dogs affected by OA before and after the treatments. The study was designed as a clinical, randomized, controlled and prospective study. Sixty client-owned dogs were randomized in the R group (n = 30, robenacoxib 1 mg/kg/day for 30 days) and in the UC-II group (n = 30, UC-II 1 tablet/day for 30 days). Thirty days after the beginning of the treatment (T30), the dogs were reassessed for the LOAD, MOBILITY and CLINICAL scores. Based on the data obtained from the study, a significant reduction in LOAD and MOBILITY scores was recorded between T0 and T30 with a similar magnitude among the two groups (R = 31.5%, p < 0.001; UC-II = 32.7%, p = 0.013). The results of this study showed that UC-II and robenacoxib were able to similarly improve mobility of dogs affected by OA.
Highlights
Osteoarthritis (OA) is a chronic inflammatory disease that affects the entire joint tissue [1]
The results of this study showed that undenatured type-II collagen (UC-II) and robenacoxib were able to improve mobility of dogs affected by OA
The results of this study show that UC-II, to robenacoxib, is able to improve the mobility impairment, as assessed by the Liverpool Osteoarthritis in Dogs (LOAD) of dogs affected by a mild/moderate lameness induced by OA
Summary
Osteoarthritis (OA) is a chronic inflammatory disease that affects the entire joint tissue [1]. The new evidences related to the pathogenesis of this disease consider it a multifactorial disorder in which low-grade chronic inflammation has a central role. This inflammation plays a early stage role in the course of OA, as a result of interactions between the immune system and multiple factors including local tissue damage and metabolic dysfunction [2]. Osteoarthritis is considered a functional disorder with subsequent alteration of mechanical properties resulting in decreased stability, movement and loading. Subjects suffering with OA tend to be less active, have difficulty of movement, cracking joints, stiffness, muscle wastage and visible pain [5]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.